Financial Statements

Below is the link for the financial statements for Celgene Corporation for the fiscal year ending 2015.

http://ir.celgene.com/sec.cfm?view=all

When you arrive at this website, please do the following.

First, under View, select Annual Filings using the drop-down arrow labeled All Filings and then select 2016 using the drop-down arrow labeled Year,

You should select the 10k dated 2/11/2016 and choose to download in PDF, HTML, or Excel format. The PDF format is the best format for searching.

Below is the link for the financial statements for Gilead Sciences, Inc. for the fiscal year ending 2015.

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-sec

First, select 2016 under the Year filter using the drop-down arrow labeled All Years and then select Annual filings under the Groupings filter using the drop-down arrow labeled All Forms. Press the large Search button to access the requested annual filing for 2016.

You should select the 10k dated 2/24/2016, and choose to download it in PDF, Word, or Excel format. The PDF format is the best format for searching.

Description

Using the financial statements for Celgene Corporation and Gilead Sciences, Inc., respectively, you will calculate and compare the financial ratios listed further down this document for the fiscal year ending 2015, and prepare your comments about the two companies performances based on your ratio calculations.

Overall Requirements

For the Final Submission:

Your final Excel workbook submission should contain the following. You cannot use any other software but Excel to complete this project.

A Completed Worksheet Title Page tab, which is really a cover sheet with your name, the course, the date, your instructors name, and the title for the project.

A Completed Worksheet Profiles tab which contains a one-paragraph description regarding each company with information about their history, what products they sell, where they are located, and so forth.

All 16 ratios for each company with the supporting calculations and commentary on your Worksheet Ratio tab. Supporting calculations must be shown either as a formula or as text typed into a different cell. The ratios are listed further down this document. Your comments for each ratio should include more than just a definition of the ratio. You should focus on interpreting each ratio number for each company and support your comments with the numbers found in the ratios. You need to specifically state which company performed better for each ratio.

The Summary and Conclusions Worksheet tab is an overall comparison of how each company compares in terms of the major category of ratios described in Chapter 13 of your textbook. A nice way to conclude is to state which company you think is the better investment and why.

The Bibliography Worksheet tab must contain at least your textbook as a reference. Any other information that you use to profile the companies should also be cited as a reference.

Required Ratios for Final Project Submission

Earnings per Share of Common Stock

Current Ratio

Gross (Profit) Margin Percentage

Rate of Return (Net Profit Margin) on Sales

Inventory Turnover

Days Inventory Outstanding (DIO)

Accounts Receivable Turnover

Days Sales Outstanding (DSO)

Asset Turnover

Rate of Return on Total Assets (ROA)

Debt Ratio

Times-Interest-Earned Ratio

Dividend Yield [For the purposes of this ratio, use Yahoo Finance to look up current dividend per share and stock price; just note the date that you looked up this information.]

Rate of Return on Common Stockholders Equity (ROE)

Free cash flow

Price-Earnings Ratio (Multiple) [For the purpose of this ratio, look up the market price per share as of December 31, 2015 for Celgene Corporation and for Gilead Sciences, Inc..]

Celgene

Created by EDGAR Online, Inc.
CELGENE CORP /DE/
INCOME_STATEMENT
Form Type: 10-K
Period End: Dec 31, 2015
Date Filed: Feb 11, 2016
Table Of Contents
				Years ended December 31,
		2015	2014	2013	2012	2011
	Consolidated Statements of
	Income:
	Total revenue	$9,256.00	$7,670.40	$6,493.90	$5,506.70	$4,842.10
	Costs and operating expenses	7,001.40	5,151.40	4,685.00	3,760.30	3,399.40
	Operating income	2,254.60	2,519.00	1,808.90	1,746.40	1,442.70
	Interest and investment income,
	net	31.10	28.20	22.00	15.30	25.90
	Interest (expense)	(310.60)	(176.10)	(91.60)	(63.20)	(42.70)
	Other income (expense), net	48.40	(43.70)	(73.90)	(17.00)	(6.40)
	Income before income taxes	2,023.50	2,327.40	1,665.40	1,681.50	1,419.50
	Income tax provision	421.50	327.50	215.50	225.30	102.10
	Net income	$1,602.00	$1,999.90	$1,449.90	$1,456.20	$1,317.40
	Less: Net loss attributable to
	non-controlling interests	-	-	-	-	0.70
	Net income attributable to
	Celgene	$1,602.00	$1,999.90	$1,449.90	$1,456.20	$1,318.10
	Net income per share
	attributable to Celgene:*
	Basic	$2.02	$2.49	$1.75	$1.69	$1.45
	Diluted	$1.94	$2.39	$1.68	$1.65	$1.42
	Weighted average shares:*
	Basic	792.20	802.70	827.70	861.90	910.70
	Diluted	824.90	836.00	860.60	881.60	925.50
				As of December 31,
		2015	2014	2013	2012	2011
	Consolidated Balance Sheets
	Data:
	Cash, cash equivalents and
	marketable securities	$6,551.90	$7,546.70	$5,687.00	$3,900.30	$2,648.20
	Total assets	27,053.40	17,340.10	13,378.20	11,734.30	10,005.90
	Short-term borrowings and
	current portion of long-term
	debt	-	605.90	544.80	308.50	526.70
	Long-term debt, net of discount	14,250.40	6,265.70	4,196.50	2,771.30	1,275.60
	Retained earnings	8,074.40	6,472.40	4,472.50	3,022.60	1,566.40
	Total equity	5,919.00	6,524.80	5,589.90	5,694.50	5,512.70

Gilead

GILEAD SCIENCES INC

10-K

02/24/2016

SELECTED CONSOLIDATED FINANCIAL DATA

Year Ended December 31,

2015

2014

2013

2012

2011

CONSOLIDATED STATEMENT OF INCOME DATA:

Total revenues (1)

$32,639

$24,890

$11,202

$9,702

$8,385

Total costs and expenses (1)

$10,446

$9,625

$6,678

$5,692

$4,596

Income from operations

$22,193

$15,265

$4,524

$4,010

$3,790

Provision for income taxes

$3,553

$2,797

$1,151

$1,038

$862

Net income attributable to Gilead

$18,108

$12,101

$3,075

$2,592

$2,804

Net income per share attributable to Gilead

$12.37

$7.95

$2.01

$1.71

$1.81

common stockholders - basic

Shares used in per share calculation-basic

1,464

1,522

1,529

1,515

1,550

Net income per share attributable to Gilead

$11.91

$7.35

$1.81

$1.64

$1.77

common stockholders - diluted

Shares used in per share calculation-diluted

1,521

1,647

1,695

1,583

1,580

Cash dividends declared per share

$1.29

$0

$0

$0

$0

____________________________

Created by Morningstar Document Research.

http://documentresearch.morningstar.com/

GILEAD SCIENCES INC
10-K
02/24/2016
SELECTED CONSOLIDATED FINANCIAL DATA
	December 31,
	2015				2014				2013				2012				2011
CONSOLIDATED BALANCE SHEET DATA:
Cash, cash equivalents and marketable	$26,208				$11,726				$2,571				$2,582				$9,964
securities (2)
Working capital (2)	$14,872				$11,953				$590				$1,918				$11,432
Total assets (2)	$51,839				$34,664				$22,579				$21,240				$17,303
Other long-term obligations (3)	$395				$586				$262				$281				$180
Senior unsecured notes, convertible senior	$22,178				$12,404				$6,636				$8,224				$7,606
notes
and credit facility (2)
Retained earnings	$18,001				$12,732				$6,106				$3,705				$1,777
Total stockholders' equity	$19,113				$15,819				$11,745				$9,544				$6,867
____________________________
Created by Morningstar Document Research.
http://documentresearch.morningstar.com/ Please show all the working for clear understanding, thanks